Efficacy of sertraline for post-stroke depression

Abstract

Background: Depression is a prevalent disorder for patients with stroke. Clinical researches indicate that sertraline is utilized to treat post-stroke depression (PSD) effectively. However, no systematic review has investigated this issue yet presently. Thus, this study aims to systematically assess the efficacy and safety of sertraline for patients with PSD. Methods: Literature sources will be divided into 2 sections: electronic sources and manual sources. We will search electronic literature sources as follows: EMBASE, MEDICINE, Web of Science, Cochrane Library, Allied and Complementary Medicine Database, Chinese Biomedical Literature Database, and China National Knowledge Infrastructure from their inceptions to the February 28, 2019. Manual sources include dissertations, ongoing trials, and conference abstracts. Two reviewers will select the literatures, extract and collect data information, and evaluate the risk of bias independently. Statistical analysis will be carried out by using RevMan 5.3 software. Results: Primary outcome is depression. It can be measured by Hamilton depression scale, Beck Depression Inventory, or any other scales. Secondary outcome are anxiety (as assessed by Hamilton anxiety scale, or other tools) response rate, activities of daily living (as measured by Barthel Index, or other scales), quality of life (as measured by 36-Item Short Form Health Survey), and safety. Conclusions: The results of this systematic review may summarize the up-to-date evidence on the efficacy and safety of sertraline for patients with PSD. Ethics and dissemination: This systematic review will not need any ethical approval, because it will not analyze any individual patient data. The findings of this study are expected to disseminate at peer-reviewed journals.

Association between Economic Status and Post-stroke Depression in Middle and Older Age: Results from China Health and Retirement Longitudinal Study (CHARLS)

“…In recent decades, there has been growing recognition of the strong association between stroke and depression; however, the exact mechanism of how they occur together is still not fully understood (15). The interaction between stroke and depression is believed to play a signi cant role in developing poststroke depression (PSD) (26).…”

Salvianolic Acids for Injection Combined with Conventional Treatment for Patients with Acute Cerebral Infarction: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

“…anti-cerebral ischemic injury, improve neurobehavioral score, reduce cerebral infarction volume, reduce IL-1β, IL-6, increase IL-10, inhibit TLR4/NF-κB signaling pathway [10,11];…”

“…increase oxidative stress molecules SOD, GSH levels and ATP content, reduce MDA and lactic acid content; enhance mitochondrial ATPase activity, resist lipid peroxidation, effectively scavenge oxygen free radicals and enhance energy metabolism [10,12–14];…”

Post-stroke depression and the abilities of antidepressants to enhance the effectiveness of neurorehabilitation

“…Следует учитывать, что появляются новые антидепрессанты, эффекты которых выходят за рамки ожидаемых результатов. Так, например, антидепрессант вортиоксетин продемонстрировал, помимо тимоаналептического (антидепрессивного) действия, отчетливый прокогнитивный эффект [31]. Представляется целесообразным проведение дальнейших контролируемых исследований новых препаратов, включая обязательное изучение вопросов безопасности, оптимальных доз, длительности лечения.…”